Clinical Trials Browser

Terminated × Interventional × idelalisib × Clear all

NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Phase 1 Terminated

203 enrolled 43 charts

B-cell Malignancies

NCT03890289 2024-11-21

GAUDEALIS

Phase 2 Terminated

5 enrolled 13 charts

Lymphoma, Follicular

NCT03151057 2024-03-12

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Phase 1 Terminated

16 enrolled 11 charts

LymphoidOther hematologic neoplasm

Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03257722 2024-02-28

PIL

Phase 1/2 Terminated

4 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT04699461 2023-10-23

LOTIS-6

Phase 2 Terminated

6 enrolled 9 charts

Lymphoma, Lymphoma, Follicular

NCT02536300 2023-08-14

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Phase 3 Terminated

96 enrolled 22 charts

Lymphoma, Follicular

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03742323 2021-09-05

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

NCT02538614 2020-11-25

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Phase 1 Terminated

2 enrolled 5 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01796470 2020-06-02

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Phase 2 Terminated

66 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02739360 2020-03-04

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Phase 4 Terminated

3 enrolled 5 charts

Lymphoid Malignancies

NCT01090414 2019-08-28

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Phase 1/2 Terminated

202 enrolled 18 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01539291 2019-08-20

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

Phase 3 Terminated

161 enrolled 34 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01659021 2019-08-14

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Phase 3 Terminated

261 enrolled 21 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02258529 2019-05-14

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Phase 2 Terminated

10 enrolled 10 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01980875 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 Terminated

57 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01980888 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 Terminated

311 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02044822 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Phase 2 Terminated

102 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01203930 2018-11-16

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Phase 2 Terminated

105 enrolled 16 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01732913 2018-11-16

Yosemite

Phase 3 Terminated

295 enrolled 9 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01732926 2018-11-16

Bridalveil

Phase 3 Terminated

475 enrolled 9 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02439138 2017-01-11

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Phase 2 Terminated

5 enrolled 8 charts

Waldenstrom Macroglobulinemia